PATIENT INFORMATION LEAFLET
Dezacor 22.75 mg/ml Oral Suspension
Deflazacort
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What is Dezacor and what it is used for
2.What you need to know before starting to take Dezacor
3.How to take Dezacor
4.Possible side effects
5.Storage of Dezacor
6.Contents of the pack and additional information
Dezacor is a medication belonging to a group of medications known as corticosteroids, which has anti-inflammatory and antiallergic properties. It has a distinct safety profile compared to other corticoids due to its lower activity on sugars and bone.
Dezacor is indicated for the treatment of:
•Rheumatic and collagen diseases.
•Skin diseases.
•Allergic diseases: bronchial asthma that does not respond to conventional treatment.
•Respiratory system diseases.
•Eye diseases.
•Blood diseases.
•Digestive system diseases.
•Renal diseases.
•Liver diseases.
Do not take Dezacor
Warnings and precautions
Be especially careful with Dezacor
Consult your doctor before starting to take this medication.
Use in athletes
Inform patients that this medication contains deflazacort, which may produce a positive result in doping control tests.
Use of Dezacor with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
In particular, inform your doctor or pharmacist if you are taking any of the following medications, as Dezacor may interact with them.
Pregnancy, breastfeeding, and fertility
Dezacor should not be used during the first trimester of pregnancy unless your doctor considers the benefits greater than the potential risk.
IMPORTANT FOR WOMEN:
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication. The consumption of medications during pregnancy can be hazardous to the embryo or fetus and should be monitored by your doctor.
Dezacor passes into breast milk, so its use is not recommended during breastfeeding.
Driving and operating machinery
No data are available, although it is advisable that, until the treatment response is satisfactory, do not perform tasks that require special attention, such as driving vehicles, operating hazardous machinery, etc.
Dezacor 22.75 mg/ml oral suspension contains sorbitol (E-420)
This medication contains sorbitol. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per mL; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Your doctor will establish the daily dose. The dosage is individual for each patient, and may be modified by your doctor based on the response to treatment.
Instructions for Correct Administration
This medication is administered orally. The bottle should be shaken before use.
The drops to be administered may be diluted immediately before taking, in sugar water or non-carbonated beverages.
Use of the Container
1.To release the dropper from its protection, hold A and, at the same time, pull B upwards.
2.Remove the metal cap from the bottle and place Y to screw on the dropper.
3.To open the bottle containing the dropper, press the cap firmly and, at the same time, unscrew.
CHILD-RESISTANT SAFETY DEVICE.
If You Take More Dezacor Than You Should
In case of overdose or accidental ingestion, call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested and go immediately to a hospital for the appropriate treatment.
If You Forget to Take Dezacor
Do not take a double dose to compensate for the missed doses.
If You Interrupt Treatment with Dezacor
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, Dezacor can produce adverse effects, although not everyone will experience them.
The adverse effects of Dezacor that have been observed primarily in long-term treatments are as follows:
•Gastrointestinal disorders: gastrointestinal ulcer.
•Nervous system disorders: headache, dizziness, agitation, sleep disorders.
•Skin and subcutaneous tissue disorders: wound healing problems, skin lesions.
•Cardiovascular and vascular disorders: increased blood pressure (hypertension), water retention in tissues (edema).
•Endocrine disorders: weight gain, worsening of diabetes mellitus, cessation of menstruation.
•Musculoskeletal and connective tissue disorders:muscle weakness, osteoporosis.
•Eye disorders: eye alterations.
With an unknown frequency (the frequency cannot be estimated from the available data): blurred vision.
The use of Dezacor with medications that produce muscle relaxation, especially when administered at high doses and for long periods of time, may produce severe muscle alterations.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es/. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
No special storage conditions are required.
Keep out of sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Dispose of the packaging 1 month after opening.
Medicines should not be thrown down the drain or in the trash. Deposit the packaging and unused medicines at the SIGRE collection point of the pharmacy.Ask your pharmacist how to dispose of the packaging and unused medicines if you are unsure. By doing so, you will help protect the environment.
Composition of Dezacor 22.75 mg/ml oral suspension drops
The active ingredient is deflazacort. Each ml of suspension contains 22.75 mg of deflazacort or each drop of suspension contains 1 mg of deflazacort.
The other components are: 70% sorbitol solution, sodium carboxymethylcellulose, aluminium magnesium silicate, polisorbate 80, benzyl alcohol, sucralose, tropical fruit aroma, citric acid monohydrate, sodium hydroxide and purified water.
Appearance of the product and content of the container:
Dezacor drops, is a homogeneous suspension of a whitish color.
This medicine is presented in amber glass vials of 20 ml including an aluminium cap and a glass dropper. The content of the container is 13 ml.
Other presentations
Dezacor is also marketed in tablets of 6 mg and 30 mg.
Marketing authorization holder
Faes Farma, S.A.
Autonomia Etorbidea, 10
48940 Leioa(Bizkaia)
Spain
Responsible for manufacturing
Faes Farma, S.A.
Maximo Agirre Kalea, 14
48940 Leioa (Bizkaia)
Spain
Or
Faes Farma, S.A.
Parque Científico y Tecnológico de Bizkaia
Ibaizabal Bidea, Edificio 901
48160 Derio (Bizkaia)
Spain
Last review date of this leaflet: January 2025
The detailed and updated information of this medicine is available on the website of the Spanish Agency of Medicaments and Health Products (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.